Skip to main content

Table 1 Baseline Characteristics

From: Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients

  HSCT 2–5 yr
(n = 26)
HSCT > 5 yr
(n = 15)
Chemotherapy
(n = 15)c
Healthy
(n = 30)
Median age, yr (IQR) 60 (55–63) 58 (53–62) 64 (57–69) 61 (57–66)
Male sex, n (%) 15 (58) 9 (60) 10 (67) 10 (33)
HSCT indication, n (%)
 Leukemia 11 (42) 4 (27) 14 (93) N/A
 Lymphoma 2 (8) 7 (47)   
 Multiple myeloma 6 (23) 1 (6.5)   
 Myelodysplastic syndrome 4 (15) 2 (13)   
 Othersa 3 (12) 1 (6.5) 1 (7)  
Type of HSCT, n (%)
 Allogeneic 20 (77) 9 (60) N/A N/A
 Autologous 6 (23) 6 (40)   
Time between HSCT or last chemo and the study date, mo (IQR) 35 (25–44) 87 (66–91) 65 (23–104) N/A
Previous shingles history, yes, n (%) 12 (46) 9 (60) 6 (40) 0 (0)
Shingles within 2 yrs after HSCT or last chemo, n (%) 9/12 (75) 6/9 (67) 5/6 (83) N/A
Median years from shingles to the study date (IQR) 3 (1.5–4)b 5 (5–7) 2.5 (1.3–6) N/A
  1. IQR Interquartile range, yr Year, mo Month, N/A Not applicable, chemo Chemotherapy
  2. aAplastic anemia (n = 3), Myeloid sarcoma (n = 1), Granulocytic sarcoma (n = 1)
  3. b1 patient could not remember the exact time of shingles
  4. cAll but one patient had acute myeloid leukemia. None had received targeted monoclonal antibody therapies
\